What can go wrong with filler?
Medically reviewed by
The LovMedSpa medical team, led by Dr. Ahmed Elsoury, MD and Dr. Mark Ennett, MD
Last reviewed: June 2026
The most serious complication from dermal filler is vascular occlusion — a blockage that occurs when filler is inadvertently injected into a blood vessel or compresses one from the outside, cutting off circulation to downstream tissue. It is rare, with reported rates ranging from roughly 1 in 10,000 to 1 in 100,000 injections depending on the anatomical site, but the potential consequences — tissue necrosis (skin death from oxygen deprivation) and, in the most severe cases, vision loss — explain why injector anatomy training, on-site hyaluronidase (the enzyme that dissolves hyaluronic acid filler), and a clinical setting are not optional features of a safe injectable practice.
The mechanism and the high-risk anatomical zones
Vascular occlusion from filler occurs through two pathways: intravascular injection (filler enters the vessel lumen directly) and extravascular compression (a large bolus placed adjacent to a vessel compresses it until flow stops). Either pathway starves downstream tissue of oxygen. The anatomical areas carrying the highest reported risk — the glabella (between the brows), the nose, and the nasolabial folds — share a common feature: small-diameter named vessels that run in predictable positions, sometimes millimeters from the injection target. The glabella carries particular concern because the supratrochlear and supraorbital arteries connect via retrograde flow pathways to the ophthalmic artery, which supplies the retina; occlusion events in this zone have a documented association with monocular vision loss. Technique choices — using a blunt-tipped cannula rather than a sharp needle in high-risk zones, injecting in small aliquots (fractions of 0.1 mL rather than a full bolus), and staying in the correct tissue plane — reduce but do not eliminate the risk. No injection technique carries zero risk of occlusion; the variable is who recognizes it and how fast.
Signs of occlusion and why hyaluronidase on-site is non-negotiable
The early signs of vascular occlusion appear within seconds to minutes of injection: immediate blanching (white discoloration at or near the injection site), pain disproportionate to the procedure, and livedo reticularis (a mottled, net-like skin pattern indicating disrupted microcirculation). Without intervention, the area progresses from dusky discoloration to blue-grey, and tissue necrosis begins within hours — the window for effective reversal narrows rapidly. The response is hyaluronidase: administered in high dose, directly into the affected area, immediately. A provider who needs to order it, retrieve it from a separate facility, or wait for pharmacy delivery has already lost the critical treatment window. The requirement is not that hyaluronidase is theoretically available — it is that it is stocked, can be drawn, and can be administered within minutes of recognition. Occlusion events involving the ophthalmic circulation present differently — sudden vision changes during or immediately after injection — and require urgent ophthalmologic escalation beyond hyaluronidase alone.
What a clinical setting specifically changes
The distinction between a clinical setting and a non-clinical one is not about the filler product — it is about response infrastructure. In a physician-supervised environment, hyaluronidase is stocked on-site; providers are trained to recognize early signs that non-clinical providers often mistake for a normal post-injection response (early blanching is easily dismissed); a supervising MD is reachable for escalation decisions; and an established protocol — not improvisation — governs the response. The risk of occlusion exists across any filler injection, regardless of setting. What a clinical setting changes is recognition speed and response capability: early signs are caught because the provider is trained to look for them, hyaluronidase is available immediately, and a physician is accessible for the decision to escalate. For hyaluronic acid filler specifically, an occlusion caught in its first minutes and treated with high-dose hyaluronidase has an excellent prognosis. One caught hours later after progressing to early necrosis does not. The setting is the margin.
Common questions
How common is vascular occlusion from filler?
Reported rates vary by study and injection site, but estimates range from roughly 1 in 10,000 to 1 in 100,000 injections — rare in absolute terms. The areas with the highest reported rates are the glabella, nose, and nasolabial folds, where named vessels run close to the injection target. Rare doesn't mean negligible: the consequences of an unmanaged occlusion — tissue necrosis or vision compromise — are serious enough that the risk profile drives every decision about technique and setting.
Is there a way to know if my injector is trained to handle complications?
The clearest signals are provider training background (physician, PA, or NP with injectable-specific training), a medical director on record, and explicit confirmation that hyaluronidase is stocked on-site. A provider who cannot tell you where their hyaluronidase is — or who deflects the question — is a meaningful flag. In a physician-led medical spa, the supervising MD's background and the clinical protocol are part of the setting's infrastructure, not an individual provider's variable.
Do all dermal fillers carry the same vascular risk?
No — and this is why the filler class matters. Hyaluronic acid (HA) filler is the only category with a direct enzymatic antidote: hyaluronidase dissolves it within minutes to hours of administration. Non-HA products — biostimulators like Sculptra (PLLA) and Radiesse (CaHA) — cannot be reversed enzymatically. If a non-HA filler causes a vascular occlusion, the response options are limited and less immediate. This is one reason HA filler remains the standard for high-risk anatomical zones and for patients receiving injectable treatment for the first time.
At LovMedSpa, dermal filler treatments are performed under the oversight of medical director Dr. Ahmed Elsoury, MD (New York and Connecticut) and Dr. Mark Ennett, MD (South Florida), with hyaluronidase stocked on-site across our Brooklyn, Manhattan, Staten Island, Aventura, and West Farms locations. A consultation is the best way to review your anatomy, goals, and the technique approach appropriate for your concern.
This is general information, not medical advice; candidacy, technique selection, and risk management are determined by a licensed provider at consultation.